Live-attenuated respiratory syncytial virus vaccine with deletion of RNA synthesis regulatory protein M2-2 and cold passage mutations is over-attenuated

Coleen K. Cunningham,Ruth A. Karron,Petronella Muresan,Elizabeth J. McFarland,Charlotte Perlowski,Jennifer Libous,Bhagvanji Thumar,Devasena Gnanashanmugam,Jack Moye,Elizabeth Schappell,Emily Barr,Vivian Rexroad,Mariam Aziz,Jaime G. Deville,Richard M. Rutstein,Lijuan Yang,Cindy Luongo,Peter Collins,Ursula J. Buchholz

Live-attenuated respiratory syncytial virus vaccine with deletion of RNA synthesis regulatory protein M2-2 and cold passage mutations is over-attenuated

2019

Coleen K. Cunningham
Ruth A. Karron
Petronella Muresan
Elizabeth J. McFarland
Charlotte Perlowski
Jennifer Libous
Bhagvanji Thumar
Devasena Gnanashanmugam
Jack Moye
Elizabeth Schappell
Emily Barr
Vivian Rexroad
Mariam Aziz
Jaime G. Deville
Richard M. Rutstein
Lijuan Yang
Cindy Luongo
Peter Collins
Ursula J. Buchholz

Background The live respiratory syncytial virus (RSV) candidate vaccine LIDcpΔM2-2 is attenuated through deletion of M2-2 and 5 cold-passage mutations.

Keywords:

Regulation of gene expression
Virology
Respiratory system
Virus
Transcription (biology)
Medicine
Titer
Infectivity
Antibody
Immunogenicity
Respiratory Syncytial Virus Vaccines
Reactogenicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations